Trade URGN stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
UroGen Pharma Ltd. (URGN) is trading at US$27.65, down 12.87% today as of Nov 20, 16:00 EST. The company has a market capitalisation of US$1.53B. Over the past 52 weeks, URGN has traded between US$16.50 and US$50.81. On Syfe you can trade URGN with $0 commission and add it to your watchlist.
| Previous close | US$31.73 |
|---|---|
| Market cap | US$1.53B |
| P/E ratio | 12.72 |
| 52-week range | US$16.50 – US$50.81 |
| Volume | 2.38M |
| Exchange | US |
UroGen Pharma Ltd.
UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.
Year: 2017
UroGen Pharma Says FDA Accepts New Drug Application for UGN-103 in Bladder Cancer
Oct 19, 1:07 PM · MT Newswires
UroGen Pharma Ltd. (URGN) stock is trading at US$27.65, -12.87% from the previous close of US$31.73.
The market cap for UroGen Pharma Ltd. (URGN) stock is approximately US$1.53B.
The price-to-earnings ratio for UroGen Pharma Ltd. (URGN) is 12.72, based on the latest reported earnings.
The 52-week high for UroGen Pharma Ltd. (URGN) stock is US$50.81.
The 52-week low for UroGen Pharma Ltd. (URGN) stock is US$16.50.
UroGen Pharma Ltd. (URGN) does not currently pay a dividend.
Stay on top of URGN
Price moves, news and earnings — straight to your inbox.
Snapshot
Popular Stocks in Singapore